BioSpace News Archive

Bio NC

Genixus Receives Federal Registration & State Licensing to Begin Production of KinetiX™ Ready-to-Administer (RTA) Syringe Platform for Acute and Critical Care Medicines

Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, today announced that it has received both federal registration and state licensing to begin commercial production of its new KinetiX™ RTA Platform brand of pre-filled syringes.

August 3, 2022
·
2 min read
Latin America compression therapy Market Size, Trends, Growth | Report 2022-2030

According to Report Study, the Latin America compression therapy market was surpassed at USD 206.57 million in 2021 and is expected to hit around USD 294.86 million by 2030, growing at a CAGR of 4.03% from 2022 to 2030.

August 3, 2022
·
5 min read
North America Non-invasive Aesthetic Treatment Market Size, Report 2022-2030

The North America non-invasive aesthetic treatment market was surpassed at USD 19.42 billion in 2021 and is expected to hit around USD 47.86 billion by 2030, growing at a CAGR of 10.54% from 2022 to 2030.

August 3, 2022
·
6 min read
Genetown

Boston Heart Diagnostics Launches Industry-Leading Small-Volume Product Line with over 40 Dried Blood Spot Tests

Boston Heart Diagnostics Corporation, a clinical laboratory within the Eurofins network of companies, announced its launch of a broad range of tests with a dried blood spot collection.

August 3, 2022
·
2 min read
Herpes Simplex Treatment Market Market Size and Analysis, Trends, Recent Developments, and Forecast Till 2030

Forecast to 2030,’ thoroughly examines the Herpes Simplex Treatment industry to provide essential data & information for the targeted readers.

August 3, 2022
·
5 min read
Hypertrophic Scar Treatment Market Size, Product Trends, Key Companies, Revenue Share Analysis, 2022–2030

Forecast to 2030,’ thoroughly examines the Hypertrophic Scar Treatment industry to provide essential data & information for the targeted readers.

August 3, 2022
·
5 min read
Drug Development

OXEIA ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 2 TRIAL FOR OXE103 FOR THE TREATMENT OF CONCUSSIONS

Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, announced today the completion of an interim analysis of its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center.

August 3, 2022
·
3 min read
Hypokalemia Market Size, Key Player Revenue, SWOT, PEST & Porter’s Analysis For 2022–2030

Forecast to 2030,’ thoroughly examines the Hypokalemia industry to provide essential data & information for the targeted readers.

August 3, 2022
·
5 min read
Vertigo Treatment Market Revenue Analysis, Company Revenue Share, Global Forecast Till 2030

Forecast to 2030,’ thoroughly examines the Vertigo Treatment industry to provide essential data & information for the targeted readers.

August 3, 2022
·
5 min read
FDA

AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

AnHeart Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational ROS-1 inhibitor taletrectinib for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

August 3, 2022
·
4 min read